Cosmos Health Receives Additional 180-Day Compliance Period from Nasdaq
MWN-AI** Summary
Cosmos Health Inc. (NASDAQ:COSM), a diversified healthcare group engaged in research and development, manufacturing, and distributing healthcare products, has received a 180-day extension from the Nasdaq Stock Market to comply with its minimum bid price requirement. This extension, effective until November 3, 2025, follows the company's notification of non-compliance due to its stock price remaining below the $1 threshold for 30 consecutive business days, which was first communicated on November 6, 2024. The initial compliance period expired on May 5, 2025.
Despite the bid price issue, Cosmos Health continues to meet all other Nasdaq listing requirements. The company plans to regain compliance by ensuring that its stock price meets or exceeds $1 for at least ten consecutive business days within the extended period. If successful, Nasdaq will then confirm compliance and close the matter.
CEO Greg Siokas expressed optimism about the company's strategic priorities and their commitment to creating long-term value for shareholders. He acknowledged Nasdaq’s ongoing support and expressed confidence in regaining compliance within the allotted timeframe.
Founded in 2009, Cosmos Health operates globally, owning a portfolio of proprietary pharmaceutical and nutraceutical brands, such as Sky Premium Life® and C-Sept®. The company also manufactures healthcare products through its subsidiary, Cana Laboratories, under strict European regulations, and is expanding its presence across Europe, Asia, and North America. Their innovative R&D initiatives focus on critical health issues, while the recent acquisition of ZipDoctor, Inc. signals their venture into telehealth.
With its strategic focus and commitment, Cosmos Health aims to navigate its challenges in the stock market while advancing its healthcare initiatives.
MWN-AI** Analysis
Cosmos Health Inc. (NASDAQ:COSM) has received a vital opportunity to regain compliance with Nasdaq's minimum bid price requirement following the extension of a 180-day compliance period through November 3, 2025. This development signals a potential turning point for the company, which has faced challenges maintaining a stock price above the $1.00 threshold. Investors should consider several factors when assessing this situation.
Firstly, the extension provided by Nasdaq indicates that the company is still considered viable and meets other listing criteria, except for the bid price rule. This reflects a level of confidence in Cosmos Health’s operational foundation and long-term strategy, led by CEO Greg Siokas, who has emphasized the company’s commitment to executing its strategic priorities.
Cosmos Health operates within diversified healthcare segments, including pharmaceutical and nutraceutical products, telehealth services, and innovative R&D initiatives targeting significant health issues. This diverse portfolio may provide a buffer against sector volatility and can appeal to a broader investor base. The acquisition of ZipDoctor, enhancing the company's telehealth capabilities, is particularly relevant in today’s digital health landscape.
However, risks remain. The company must not only achieve but sustain a share price above the compliance threshold for at least ten consecutive business days to confirm compliance. Market conditions, competitive pressures, and operational challenges, including potential macroeconomic factors like the geopolitical climate, could significantly influence stock performance.
Investors should engage in careful monitoring of Cosmos Health's stock activity during this compliance period. A steady upward momentum could signal a turnaround and present an attractive buying opportunity; conversely, persistent weakness may warrant caution. In summary, Cosmos Health’s recent compliance extension offers a glimmer of hope but necessitates vigilant observation from investors.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
CHICAGO, May 06, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has received formal notice from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is eligible for an additional 180 calendar day period, through November 3, 2025, to regain compliance with the Nasdaq’s minimum bid price requirement.
As previously disclosed, on November 6, 2024, the Company was notified by Nasdaq that it was not in compliance with the $1.00 minimum bid price requirement, as the closing bid price of the Company’s common stock had remained below $1.00 for 30 consecutive business days. The initial 180-day compliance period expired on May 5, 2025.
The second compliance period was granted as the Company continues to meet all other applicable listing requirements for the Nasdaq Capital Market, other than the bid price rule. In accordance with Nasdaq rules, the Company has indicated its intention to regain compliance within the second compliance period. If at any time during this second compliance period the closing bid price of the Company’s common stock meets or exceeds $1.00 per share for at least 10 consecutive business days, Nasdaq will provide written confirmation of compliance and the matter will be closed.
Greg Siokas, CEO of Cosmos Health, stated: “We remain focused on executing our strategic priorities and delivering long-term value for our shareholders. We appreciate Nasdaq’s continued support and are confident in our ability to meet the listing requirements within the extended timeframe.”
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com , www.skypremiumlife.com , www.cana.gr , www.zipdoctor.co , www.cloudscreen.gr , as well as LinkedIn and X .
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website ( www.sec.gov ). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
+44 207 0971 653
Disclaimer
This electronic content is for the purposes of solicitation subscriptions for Market Wire News. Market Wire News expects to generate new advertisement revenue resulting from the distribution of this electronic content. The amount of which is unknown at this time. Market Wire News is not a registered investment adviser or broker-dealer. This electronic content does not provide a professional analysis of a COSM financial position. COSM financial position and all other information regarding the featured Company should be verified directly with COSM. This electronic content is provided as an information service only, and any statements and opinions in this electronic content should not be construed as an offer or solicitation to buy or sell any security. Market Wire News accepts no liability for any loss arising from an investor's reliance on or use of this electronic content. An investment in COSM is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Market Wire News does not own, buy, sell or plans to own, buy, sell, and of COSM shares. This electronic content contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Compensation: Market Wire News and its affiliates has received six thousand dollars for Market Wire News advertising services from Relqo Media LLC for Brand Awareness Distribution, Corporate Communications, News, Press Release Enhancement and Social Media Solutions starting 2026-05-31 and ending 2026-06-05 provided by Market Wire News. To date, we have received a total of six thousand dollars. Please read our full disclaimer for compensation and more detailed information.
FAQ**
What specific strategies does Cosmos Holdings Inc. (COSM) plan to implement during the extended compliance period to ensure its stock price meets the required $1.00 minimum bid price?
Given its diverse portfolio, how does Cosmos Holdings Inc. (COSM) prioritize its R&D partnerships to best position itself against major health disorders like obesity and cancer?
What impact do the geopolitical tensions, such as the war in Ukraine, have on Cosmos Holdings Inc. (COSM)'s international operations and market expansion plans?
Can you elaborate on the expected synergies between Cosmos Holdings Inc. (COSM) and its newly acquired telehealth platform, ZipDoctor, in enhancing their healthcare service offerings?
**MWN-AI FAQ is based on asking OpenAI questions about Cosmos Health Inc. (NASDAQ: COSM).
NASDAQ: COSM
COSM Trading
2.67% G/L:
$0.2572 Last:
2,524,082 Volume:
$0.2525 Open:
